Literature DB >> 31257121

Validation of a semi automatic device to standardize quantification of Colony-Forming Unit (CFU) on hematopoietic stem cell products.

Mélanie Velier1, Anne-Line Chateau2, Carine Malenfant3, Sarah Ouffai3, Boris Calmels4, Christian Chabannon5, Claude Lemarié4.   

Abstract

Accurate characterization of hematopoietic stem cells (HSC) products is needed to better anticipate the hematopoietic reconstitution and the outcome in patients. Although CD34+ viable cells enumeration is a key predictor of time to correction of aplasia, it does not fully inform about functionality of cells contained in the graft. CFU assay is the gold standard in vitro potency assay to assess clonogenicity of HSC and consists on the count and identification of colonies several days after culture in a semi solid media. Manual count of colonies with optic microscope is the most commonly used method but its important variability and subjectivity hinders the universal implementation of this potency assay. The aim of this study is to validate a standardized method using the STEMvision™ system, the first semi-automated instrument for imaging and scoring hematopoietic colonies, according to French and European recommendations. Results obtained highlight better performance criteria with STEMvision™ system than the manual method. This semi-automatic device tends to reduce the coefficients of variation of repeatability, inter-operator variability and intermediate precision. This newly available platform could represent an interesting option, significantly improving performances of CFU assays used for the characterization of hematopoietic progenitors.
Copyright © 2019 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31257121     DOI: 10.1016/j.jcyt.2019.06.005

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  1 in total

1.  Related versus unrelated allogeneic HPC graft cryopreservation: a single-center experience in the context of the global COVID-19 pandemic.

Authors:  B Mfarrej; C Lemarié; A Granata; T Pagliardini; C Malenfant; P Lignée; M Fays; D Blaise; C Chabannon; B Calmels
Journal:  Bone Marrow Transplant       Date:  2021-04-12       Impact factor: 5.174

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.